-
FDA Extends Review Period For CTI BioPharma's Bone Marrow Cancer Candidate
Wednesday, December 1, 2021 - 7:29am | 347Read More...The FDA has extended the review period for CTI BioPharma Corp's (NASDAQ: CTIC) pacritinib marketing application for myelofibrosis. The application for pacritinib covers adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-...
-
Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial
Wednesday, August 18, 2021 - 9:25am | 192Read More...Galecto Inc (NASDAQ: GLTO) has announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. Myelofibrosis, a form of chronic leukemia, is a rare type of blood cancer in which the normal bone marrow is destroyed by...
-
Geron Stock Trading Is Higher On Reinforcing Imetelstat's Approach For Myelofibrosis Treatment, With Data Publication In Journal
Friday, June 18, 2021 - 6:31am | 285Read More...Geron Corporation (NASDAQ: GERN) stock is trading higher during the premarket in reaction to data publication from the IMbark Phase 2 trial of imetelstat for myelofibrosis (MF) in the Journal of Clinical Oncology. The publication highlights the clinical benefits observed in the...
-
Geron Shares Seen Range-Bound On Lack Of Major Data Until Late 2017
Friday, August 19, 2016 - 12:28pm | 360Read More...BTIG expects Geron Corporation (NASDAQ: GERN) shares to be range-bound until major data release, potentially in late 2017 or 2018. Geron's lead compound imetelstat, an inhibitor of telomerase partnered with Johnson & Johnson (NYSE: JNJ)'s Janssen showed impressive activity in multiple...
